Mucodel Pharma Announces Patent Allowance for Mucodel’s Co-Gel Buccal Naloxone (Exonal™) Greensboro, NC, March 15, 2017 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) announced today that it has received a notice of allowance from the United States Patent and Trademark Office for...

Mucodel Pharma Announces Successful Completion of Buccal Naloxone Pilot Clinical Study GREENSBORO, N.C., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving buccal naloxone (Exonal™), a...